Patents Examined by Sheela Huff
  • Whole blood/mitogen assay for the early detection of a subject with cancer and kit
    Patent number: 6280962
    Abstract: This invention provides a method of detecting a subject having ovarian or breast cancer, comprising the following steps; a) obtaining a whole blood sample from the subject; b) incubating the whole blood sample in a culture in the presence of a media containing a mitogen, so as to induce polyclonal activation of lymphocytic cells to produce tumor antigen associated antibodies; c) exposing the resultant culture of step b) to an specific tumor antigen, thereby allowing an antigen-antibody immune complex to form; d) detecting the antigen-antibody immune complex of step c); wherein the presence of tumor antigen associated antibody is indicative of the subject having the cancer.
    Type: Grant
    Filed: December 13, 1996
    Date of Patent: August 28, 2001
    Assignee: Yoreh Biotechnologies Ltd.
    Inventor: Tamar Jehuda Cohen
  • Methods and materials for the treatment of prostatic carcinoma
    Patent number: 6280742
    Abstract: The present invention related generally to materials and methods for reduction and/or alleviation of prostatic and prostatic-related (metatastic) carcinoma via the administration of disclosed compositions, immunotherapeutic agents, or antibodies.
    Type: Grant
    Filed: June 17, 1998
    Date of Patent: August 28, 2001
    Assignee: Zonagen, Inc.
    Inventors: Christopher Allen Seid, Gurpreet Singh
  • Antibodies to bladder cancer nuclear matrix proteins and their use
    Patent number: 6280956
    Abstract: Nuclear matrix proteins (NMP) which are characterized by a defined expression in bladder tissue are provided, which can be used to generate antibodies that differentiate between normal and cancerous bladder tissue. These NMPs are useful markers in diagnosing and monitoring the stage of malignancy of a bladder cell and treating bladder cell proliferative disorders associated with the NMP. Also provided are substantially purified polypeptides and nucleotide sequences encoding the NMPs of the invention.
    Type: Grant
    Filed: August 28, 1998
    Date of Patent: August 28, 2001
    Assignee: University of Pittsburgh
    Inventor: Robert H. Getzenberg
  • Rh blood group antigen compositions and methods of use
    Patent number: 6280958
    Abstract: Disclosed are novel protein and peptide compositions comprising soluble and bound forms of immunologically-active blood group antigens including mammalian Rh antigens. In preferred embodiments methods for the isolation and purification of serologically-active human Rh antigens such as D, c, C, E, and e are disclosed. Also disclosed are methods for the adsorption of immunologically-active Rh antigens to solid supports. Diagnostic kits, methods, and devices for the detection of Rh antibodies in clinical and non-clinical samples are also disclosed. Devices, compositions and methods for the isolation, purification and quantitation of anti-Rh antibodies from solution are also provided.
    Type: Grant
    Filed: January 20, 2000
    Date of Patent: August 28, 2001
    Assignees: Board of Regents, the University of Texas Systems, Baylor College of Medicine
    Inventors: L. Scott Rodkey, Marwan A. Yared, Kenneth J. Moise, Jr.
  • Proteins associated with apoptosis
    Patent number: 6281334
    Abstract: The invention provides three human proteins associated with cell proliferation, referred to collectively as “APOP” and individually as “APOP-1”, “APOP-2”, and “APOP-3”, and polynucleotides which identify and encode APOP. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for preventing and treating disorders associated with expression of APOP.
    Type: Grant
    Filed: September 30, 1999
    Date of Patent: August 28, 2001
    Assignee: Incyte Genomics, Inc.
    Inventors: Jennifer L. Hillman, Henry Yue, Pretti Lal, Purvi Shah, Neil C. Corley
  • Serine dehydratase homolog
    Patent number: 6277619
    Abstract: The invention provides a human serine dehydratase homolog (SDHH) and polynucleotides which identify and encode SDHH. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating or preventing disorders associated with expression of SDHH.
    Type: Grant
    Filed: June 1, 1998
    Date of Patent: August 21, 2001
    Assignee: Incyte Genomics, Inc.
    Inventors: Preeti Lal, Neil C. Corley, Karl J. Guegler, Chandra Patterson
  • Anti-CEA antibody designated 806.077, hybridoma and method of manufacture
    Patent number: 6277599
    Abstract: An anti-CEA monoclonal antibody, designated 806.077, of murine origin is useful for the diagnosis and therapy of cancer. The antibody complementarity determining regions have the following sequences: heavy chain CDR1 DNYMH, CDR2 WIDPENGDTE YAPKFRG, CDR3 LIYAGYLAMD Y; and light chain CDR1 SASSSVTYMH, CDR2 STSNLAS, CDR3 QQRSTYPLT. The antibody optionally is humanized and can be in the form of a conjugate with either an enzyme, such as carboxypeptidase, or a co-stimulatory molecule such as the extracellular domain of human B7.1.
    Type: Grant
    Filed: October 29, 1998
    Date of Patent: August 21, 2001
    Assignee: Zeneca Limited
    Inventors: Clive Graham Copley, Michael Derek Edge, Stephen Charles Emery
  • Inhibiting proliferation of cancer cells
    Patent number: 6274305
    Abstract: A method of testing cancer cells is described. Assays are provided for determining the potential for inhibiting cancer cells proliferation using albumin-derived peptides. The methods of the present invention allow for drug screening as well as for evaluation of biopsied tumors.
    Type: Grant
    Filed: December 19, 1996
    Date of Patent: August 14, 2001
    Assignee: Tufts University
    Inventors: Carlos Sonnenschein, Ana M. Soto
  • Melanoma antigens and their use in diagnostic and therapeutic methods
    Patent number: 6270778
    Abstract: The present invention provides a nucleic acid sequence encoding a melanoma antigen recognized by T lymphocytes, designated MART-1. This invention further relates to bioassays using the nucleic acid sequence, protein or antibodies of this invention to diagnose, assess or prognoses a mammal afflicted with melanoma or metastata melanoma. This invention also provides immunogenic peptides derived from the MART-1 melanoma antigen and a second melanoma antigen designated gp100. This invention further provides immunogenic peptides derived from the MART-1 melanoma antigen or gp100 antigen which have been modified to enhance their immunogenicity. The proteins and peptides provided can serve as an immunogen or vaccine to prevent or treat melanoma.
    Type: Grant
    Filed: March 12, 1999
    Date of Patent: August 7, 2001
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Yutaka Kawakami, Steven A. Rosenberg
  • PSCA: prostate stem cell antigen
    Patent number: 6267960
    Abstract: The present invention provides methods for inhibiting the growth of prostate tumor cells expressing Prostate Stem Cell Antigen (PSCA), the methods comprising administering to a patient a monoclonal antibody which binds specifically to the extracellular domain of PSCA in an amount effective to inhibit growth of the prostate tumor cells.
    Type: Grant
    Filed: March 10, 1998
    Date of Patent: July 31, 2001
    Assignee: The Regents of the University of California
    Inventors: Robert E. Reiter, Owen N. Witte
  • Methods and compositions for inhibiting tumor cell growth
    Patent number: 6264948
    Abstract: A method of suppressing tumor cell growth, comprising administering to a mammal in need thereof an amount of an inhibitor of eosinophilia sufficient to result in suppression of tumor cell growth is disclosed.
    Type: Grant
    Filed: December 8, 1998
    Date of Patent: July 24, 2001
    Assignee: Beth Israel Deaconess Hospital, Inc.
    Inventors: David T. W. Wong, Peter F. Weller
  • Tissue specific prodrug
    Patent number: 6265540
    Abstract: The invention provides novel peptide prodrugs which contain cleavage sites specifically cleaved by prostate specific antigen (PSA). These prodrugs are useful for substantially inhibiting the non-specific toxicity of a variety of therapeutic drugs. PSA is secreted by prostatic glandular cells. Upon cleavage of the prodrug by PSA, the therapeutic drugs are activated and exert their toxicity. Novel sesquiterpene-&ggr;-lactones are also provided by the invention, and are designed to be linked to carrier moieties such as the peptides of the invention. Methods for treating cell proliferative disorders are also featured in the invention.
    Type: Grant
    Filed: May 19, 1998
    Date of Patent: July 24, 2001
    Assignee: The Johns Hopkins University School of Medicine
    Inventors: John T. Isaacs, Samuel R. Denmeade, S. Brogger Christensen, Hans Lilja
  • Method for diagnosing cancer using specific PSCA antibodies
    Patent number: 6261791
    Abstract: The invention provides a novel prostate cell-surface antigen, designated Prostate Stem Cell Antigen (PSCA), which is widely over-expressed across all stages of prostate cancer, bladder cancer and bone metastasis of prostate cancer. Antibodies specific to PSCA are used for diagnosis of these cancers.
    Type: Grant
    Filed: May 25, 1999
    Date of Patent: July 17, 2001
    Assignee: The Regents of the University of California
    Inventors: Robert E. Reiter, Owen N. Witte
  • Compounds for immunotherapy of prostate cancer and methods for their use
    Patent number: 6262245
    Abstract: Compounds and methods for treating prostate cancer are provided. The inventive compounds include polypeptides containing at least a portion of a prostate tumor protein. Vaccines and pharmaceutical compositions for immunotherapy of prostate cancer comprising such polypeptides, or DNA molecules encoding such polypeptides, are also provided, together with DNA molecules for preparing the inventive polypeptides.
    Type: Grant
    Filed: February 25, 1998
    Date of Patent: July 17, 2001
    Assignee: Corixa Corporation
    Inventors: Jiangchun Xu, Davin C. Dillon
  • Methods for detecting the presence of a PSCA protein using PSCA antibodies
    Patent number: 6261789
    Abstract: The invention provides methods for detecting the presence of a PSCA protein comprising contacting the sample with PSCA antibodies designated 1G8 (ATCC No. HB-12612), 2A2 (ATCC No. HB-12613), 2H9 (ATCC No. HB-12614), 3C5 (ATCC No. HB-12616), 3E6 (ATCC No. HB12618), 3G3 (ATCC No. HB-12615), or 4A10 (ATCC No. HB-12617).
    Type: Grant
    Filed: February 17, 1999
    Date of Patent: July 17, 2001
    Assignee: The Regents of the University of California
    Inventors: Robert E. Reiter, Owen N. Witte
  • PSCA antibodies and hybridomas producing them
    Patent number: 6258939
    Abstract: The invention provides a novel prostate cell-surface antigen, designated Prostate Stem Cell Antigen (PSCA), which is widely over-expressed across all stages of prostate cancer, including high grade prostatic intraepithelial neoplasia (PIN), androgen-dependent and androgen-independent prostate tumors.
    Type: Grant
    Filed: December 2, 1998
    Date of Patent: July 10, 2001
    Assignee: The Regents of the University of California
    Inventors: Robert E. Reiter, Owen N. Witte
  • EBV-infected stomach cancer cell line
    Patent number: 6258598
    Abstract: An EBV strain infecting epithelial cells and a stomach cancer cell line cancerated by EBV are established to clarify the mechanism of canceration of epithelial cells into stomach cancer by EBV and to develop a chemotherapeutic agent for stomach cancer cancerated by EBV. Further, a stomach cancer cell line stably producing EBV-related antigens is established to develop a diagnostic drug for stomach cancer cancerated by EBV. According to the present invention, GTC-4 cell line was established through culture of stomach cancer tissues. GTC-4 produced the EBV strain infecting epithelial cells and simultaneously produced EBV-related antigens stably in the supernatant.
    Type: Grant
    Filed: August 30, 1999
    Date of Patent: July 10, 2001
    Assignee: Eisai Co., Ltd.
    Inventors: Masako Tajima, Masakatsu Takanashi, Yukihisa Miyazawa, Toshio Takeshima, Kota Okinaga
  • Cyclic GMP phosphodiesterase
    Patent number: 6255456
    Abstract: The invention provides a human cyclic GMP phosphodiesterase (PDE9A) and polynucleotides which identify and encode PDE9A. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for treating or preventing disorders associated with expression of PDE9A.
    Type: Grant
    Filed: January 29, 1999
    Date of Patent: July 3, 2001
    Assignee: Incyte Genomics, Inc.
    Inventors: Douglas A. Fisher, Douglas H. Gooding, David Gray Streeter
  • Glycosylated humanized B-cell specific antibodies
    Patent number: 6254868
    Abstract: A humanized specific monoclonal antibody or antibody fragment, especially a B-cell specific antibody or antibody fragment, is engineered to contain a glyxosylation site in the non-Fc constant region. The glycosylated antibody is useful for diagnosis and/or therapy whenever a targeting antibody or fragment is used, especially for B-cell malignancies. The carbohydrate moiety allows conjugation of labeling or therapeutic agents of increased size, without affecting the binding affinity or specificity of the antibody.
    Type: Grant
    Filed: November 17, 1998
    Date of Patent: July 3, 2001
    Assignee: Immunomedics, Inc.
    Inventors: Shui-on Leung, Hans Hansen, Zhengxing Qu
  • Antibodies which bind to NY-ESO-1 cancer associated proteins, and hybridomas which produce these antibodies
    Patent number: 6252052
    Abstract: The invention relates to antibodies which bind to the cancer associated antigen NY-ESO-1. Both polyclonal and monoclonal antibodies are part of the invention, as are chimeric forms of the antibodies, and binding portions of antibodies. Uses of these antibodies are described. Also described are truncated, recombinant forms of the cancer associated antigen.
    Type: Grant
    Filed: April 17, 1998
    Date of Patent: June 26, 2001
    Assignees: Cornell Research Foundation, Inc, Ludwig Institute for Cancer Research, Memorial Sloan-Kettering Cancer Center
    Inventors: Elisabeth Stockert, Elke Jäger, Yao-tseng Chen, Matthew Scanlan, Knuth Alexander, Lloyd J. Old